| 08/     |
|---------|
| U.S. PT |
| 0       |

|  | Docket Nun  | nber CT-2727 CNT | To I     |  |  |
|--|-------------|------------------|----------|--|--|
| FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10 |             |                  |          |  |  |
| EV 272265285                               | <del></del> | August 27, 2003  | si &     |  |  |
| Express Mail Label Nur                     | nber        | Date of Deposit  | 79/<br>E |  |  |
|  |             |                  | 1038     |  |  |

Address to:

MAIL STOP: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

reserved.

## UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **continuation** of prior Application No. CT-2727 NP 10/259,041, filed September 26, 2002.

| Applicant (or identifier):          |               | (or identifier):  | PRIESTLEY ET AL.  |  |  |  |  |
|-------------------------------------|---------------|---|---|--|--|--|--|
| Title:                              |               |   | COMPOUNDS USEFUL FOR TREATING HEPATITIS C VIRUS   |  |  |  |  |
| Encl                                | Enclosed are: |   |   |  |  |  |  |
| 1.<br>2.<br>3.                      |               | Drawings - Declaration and a. Newly b. Copy signed i. Declaration     | ncluding Claims and Abstract) - 74 pages sheets d Power of Attorney executed (original or copy) from a prior application (signed or with indication that original was d) eletion of Inventors gned statement attached deleting inventor(s) named in the prior |  |  |  |  |
| 4.                                  |               |   |   |  |  |  |  |
| 5.<br>6.                            |               | Microfiche Com<br>Nucleotide and<br>Computer<br>Paper Cop             | nputer Program (appendix)<br>/or Amino Acid Sequence Submission<br>Readable Copy<br>y<br>Verifying Identity of Above Copies   |  |  |  |  |
| 7.<br>8.<br>9.<br>10.<br>11.<br>12. |               | Preliminary Am<br>Assignment Pa<br>English Transla<br>Information Dis | endment pers (Cover Sheet & Document(s)) tion of closure Statement of Priority Document(s)  |  |  |  |  |
| $\boxtimes$                         | The           | right to elect an   | invention or species that is different from that elected in parent  |  |  |  |  |

Application No. CT-2727 NP in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby

## Filing fee calculation:

| $\boxtimes$ | Before calculating the filing fee, please enter the enclosed Preliminary Amendment. |
|-------------|---|
|             | Before calculating the filing fee, please cancel claims .                           |

| Basic Filing Fee                      |                       |                 |     |                 |   |           | \$<br>750 |   |    |
|---------------------------------------|-----------------------|-----------------|-----|-----------------|---|-----------|-----------|---|----|
| Multiple Dependent Claim Fee (\$ 280) |                       |                 |     |                 |   |           | \$        |   |    |
| Foreign Language Surcharge (\$ 130)   |                       |                 |     |                 |   | \$        |           |   |    |
|                                       | For                   | Number<br>Filed |     | Number<br>Extra |   |           | Rate      |   |    |
| Extra<br>Claims                       | Total Claims          | 15              | -20 |                 | x | \$        | 18        | = | \$ |
|                                       | Independent<br>Claims | 2               | -3  |                 | х | \$        | 84        | = | \$ |
| TOTAL FILING FEE                      |                       |                 |     |                 |   | \$<br>750 |           |   |    |

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$750. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Please address all correspondence to the address associated with Customer No. 23914, which is currently:

Stephen B. Davis Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Date: August 27, 2003

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (203) 677-6900.

Respectfully submitted,

Warren Volles

Attorney for Applicants

Warren Wolls

Reg. No. 33,810

Tel. No. (203) 677-6997